Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
13-valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine
Pediatric Infectious Disease Journal, Volume 33, No. 2, Year 2014
Notification
URL copied to clipboard!
Description
BACKGROUND:: The 13-valent pneumococcal conjugate vaccine (PCV13) has been demonstrated to be immunogenic and safe for administration to infants and children aged <5 years. PCV13 recently was approved for children and adolescents aged up to 17 years as the vaccine may be of benefit to some in this older age group. METHODS:: In this open-label study, healthy children aged ≥5 to <10 years (ie, the younger age group) previously vaccinated (≥1 dose) with 7-valent PCV (PCV7) and pneumococcal vaccine-naïve children aged ≥10 to <18 years (ie, the older age group) received 1 dose of PCV13. For the younger group, antipneumococcal immunoglobulin (Ig) G geometric mean concentrations 1 month postvaccination were compared with posttoddler dose (PCV13 or PCV7) levels from a historical control study. Opsonophagocytic activity geometric mean titers 1 month postvaccination for the older group were compared with the younger age group. Safety data were collected. RESULTS:: Five hundred and ninety-eight children were enrolled, 299 in each age group. For PCV7 serotypes, IgG geometric mean concentrations in the younger group were 8.23-53.56 μg/mL, ≥2.5-fold greater than historical posttoddler dose values. For the 6 additional serotypes, IgG geometric mean concentrations in the younger group were 2.38-21.51 μg/mL, ≥1.2-fold greater than historical posttoddler dose values. Opsonophagocytic activity geometric mean titers were similar in the older and younger age groups, except for serotype 3 which was lower in the older group. Safety was comparable in both groups. CONCLUSIONS:: PCV13 was immunogenic and safe when administered to older children and adolescents, regardless of prior PCV7 vaccination. Copyright © 2013 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Frenck, Robert W.
United States, Cincinnati
Cincinnati Children's Hospital Medical Center
Thompson, Allison R.
United States, New York
Pfizer Inc.
Senders, Shelly David
Unknown Affiliation
Devlin, Carmel
United States, New York
Pfizer Inc.
Jansen, Kathrin Ute
United States, New York
Pfizer Inc.
Gruber, William C.
United States, New York
Pfizer Inc.
Emini, Emilio A.
United States, New York
Pfizer Inc.
Scott, Daniel A.
United States, New York
Pfizer Inc.
Gurtman, Alejandra C.
United States, New York
Pfizer Inc.
Statistics
Citations: 19
Authors: 9
Affiliations: 2
Identifiers
Doi:
10.1097/INF.0000000000000056
ISSN:
15320987
Research Areas
Maternal And Child Health